GlassScriptPhysician profile
John Iamele
NPI 1275517385
$1,129.98
in general payments reported to CMS, 2019-2025
14 companies · $518 in 2025
The $518 reported for 2025 was more than what 78% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $37.18 · 2022: $121 · 2023: $329 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $846.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $261.86 | 2025 | Xiidra, Miebo |
| Sun Pharmaceutical Industries INC. | $181.53 | 2023 | Cequa |
| Visioneering Technologies, INC. | $128.12 | 2019-2025 | |
| Genzyme Corporation | $124.17 | 2019-2025 | |
| Horizon Therapeutics Plc | $122.45 | 2023 | Tepezza |
| Amgen INC. | $117.76 | 2025 | Tepezza |
| Dompe US, INC. | $50.47 | 2022 | |
| Mallinckrodt Hospital Products INC. | $29.85 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.67 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $24.31 | 2021 | |
| Alcon Vision LLC | $23.14 | 2022 | |
| Oyster Point Pharma, INC. | $17.76 | 2022 | |
| Allergan, INC. | $12.87 | 2021 | |
| Coopervision INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Iamele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.